Clinical Trials Browser

Phase 2/3 × Breast × 90 days × Clear all

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 1 FDA

Breast Neoplasms

NCT07413939 2026-03-10

BREnnA

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

NCT06062810 2026-03-09

Drugs-SNPs

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT03077841 2026-03-05

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

Phase 2/3 Suspended

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT04715958 2026-02-17

Prediction of Neoadjuvant Chemotherapy Response Using Contrast-Enhanced Ultrasound in Patients With Locally Advanced Breast Cancer

Phase 2/3 Recruiting

Anatomic Stage III Breast Cancer AJCC v8

NCT07373782 2026-01-28

Continuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cancer

Phase 2/3 Recruiting

Microcephaly, Primary Autosomal Recessive, 6, Breast Neoplasms

NCT07366840 2026-01-26

BRIGHT

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT05860465 2026-01-14

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Phase 2/3 Recruiting

Breast Neoplasms

NCT04290793 2026-01-07

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT07310758 2025-12-30

Contrast-enhanced Ultrasound for Sentinel Node Detection

Phase 2/3 Recruiting

BreastDermatologicHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Melanoma

NCT07294508 2025-12-29

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT07294534 2025-12-19

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

Phase 2/3 Not yet recruiting

Breast Neoplasms